血清糖类抗原125、人附睾蛋白4、癌胚抗原对上皮性卵巢癌患者术前临床分期的评估价值  

Evaluation value of serum carbohydrate antigen 125,human epididymis protein,4,and carcinoembryonic antigen in preoperative clinical staging of patients with epithelial ovarian cancer

作　　者：乔李 陈新华 奚旭霞 陈小军 QIAO Li;CHEN Xinhua;XI Xuxia;CHEN Xiaojun(Department of Gynecology,the First People’s Hospital of Wuhu,Wuhu 241000,Anhui,China;Department of Gynecology and Oncology,Fudan University Shanghai Cancer Center,Shanghai 200000,China)

机构地区：[1]芜湖市第一人民医院妇科,安徽芜湖241000 [2]复旦大学附属肿瘤医院妇瘤科,上海2000000

出　　处：《癌症进展》2022年第22期2295-2299,共5页Oncology Progress

基　　金：皖南医学院2020年度校教学医院科研专项立项项目(JXYY202022);芜湖市第一人民医院院级科研项目(2020WYY024I)。

摘　　要：目的探讨血清糖类抗原125(CA125)、人附睾蛋白4(HE4)、癌胚抗原(CEA)对上皮性卵巢癌患者术前临床分期的评估价值。方法收集284例上皮性卵巢癌患者的病历资料,所有患者均于初诊入院时采用酶联免疫吸附试验(ELISA)检测血清CA125、HE4、CEA水平。所有患者均接受手术治疗并明确临床分期。比较不同临床特征上皮性卵巢癌患者的血清CA125、HE4、CEA水平。采用受试者工作特征(ROC)曲线分析血清CA125、HE4、CEA单独及联合检测对上皮性卵巢癌患者术前临床分期的评估价值。结果肿瘤扩散、淋巴结转移、远处转移、Ⅲ~Ⅳ期上皮性卵巢癌患者的血清CA125、HE4、CEA水平分别明显高于无肿瘤扩散、无淋巴结转移、无远处转移、Ⅰ~Ⅱ期的患者,差异均有统计学意义(P<0.01)。血清CA125、HE4、CEA联合检测评估上皮性卵巢癌患者术前Ⅲ~Ⅳ期的曲线下面积(AUC)高于各指标单独检测,差异均有统计学意义(P<0.05)。结论肿瘤扩散、淋巴结转移、远处转移、Ⅲ~Ⅳ期上皮性卵巢癌患者的血清CA125、HE4、CEA水平均较高,三者联合检测可评估上皮性卵巢癌患者的临床分期,从而指导临床治疗。Objective To investigate the evaluation value of serum carbohydrate antigen 125(CA125),human epididymis protein 4(HE4),and carcinoembryonic antigen(CEA)in preoperative clinical staging of patients with epithelial ovarian cancer.Method The medical records of 284 patients with epithelial ovarian cancer were collected.Serum CA125,HE4,and CEA levels were detected by enzyme linked immunosorbent assay(ELISA)in all patients at the time of primary admission.All patients received surgical treatment and the clinical stage was clarified.The serum CA125,HE4,and CEA levels in epithelial ovarian cancer patients with different clinical characteristics were compared.The receiver operating characteristic(ROC)curve was drawn to analyze the evaluation value of serum CA125,HE4,and CEA alone and combined detection in preoperative clinical staging of patients with epithelial ovarian cancer.Result The serum CA125,HE4,and CEA levels of epithelial ovarian cancer patients with tumor spread,lymph node metastasis,distant metastasis,and stageⅢ-Ⅳwere significantly higher than those of patients without tumor spread,lymph node metastasis,distant metastasis,and stageⅠ-Ⅱ,the differences were statistically significant(P<0.01).The area under the curve(AUC)of serum CA125,HE4,and CEA combined detection in the evaluation ofⅢ-Ⅳstage of patients with epithelial ovarian cancer was higher than that of each index alone,and the differences were statistically significant(P<0.05).Conclusion The levels of serum CA125,HE4,and CEA in epithelial ovarian cancer patients with tumor spread,lymph node metastasis,distant metastasis,and stage III-IV are up-regulation.The combined detection of the three indicators could effectively evaluate the clinical stage of patients with epithelial ovarian cancer,and guiding the clinical treatment.

关 键 词：糖类抗原125 人附睾蛋白4 癌胚抗原 上皮性卵巢癌 临床分期 

分 类 号：R737.31[医药卫生—肿瘤]